Market Intelligence, Preclinical Progress, and Native-Conformation Reagents for Adhesion GPCR Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADGRG1 (GPR56) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | ADGRG1 Promise-ORF / Lentivirus Premade Particles. Full-length ORF for stable cell lines. Essential for preserving 7-TM conformation and GPS autoproteolysis. | View ADGRG1 Products |
| Antigen | ADGRG1 N-terminal ECD-Fc Fusion (GAIN domain inclusive). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View ADGRG1 Products |
| Benchmark Ab | Anti-ADGRG1 Recombinant Antibody (Reference Sequence). Positive control for binding and functional assays. Sequence Verified. | View ADGRG1 Products |
| Validator | ADGRG1 siRNA Set (3 unique sequences). For knockdown verification and assay specificity controls. | View ADGRG1 Products |
| Related Target A | TGM2 (Tissue Transglutaminase 2). Primary endogenous ligand for ADGRG1; essential for interaction assays. | View TGM2 Products |
| Related Target B | CD9. Tetraspanin interaction partner in membrane microdomains. | View CD9 Products |
| Related Target C | ADGRG5 (GPR114). Synergistic adhesion GPCR subfamily member; counter-screening and pathway analysis. | View ADGRG5 Products |
| Related Target D | ADGRE5 (CD97). Homology off-target liability panel inclusion. | View ADGRE5 Products |
| Related Target E | ADGRG6 (GPR126). Related adhesion GPCR in myelination and tumor microenvironment crosstalk. | View ADGRG6 Products |
| Related Target F | COL3A1 (Collagen III). Primary endogenous ligand for ADGRG1 NTD; competition binding assays. | View COL3A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native conformation & autoproteolytic GPS cleavage | Full-length ADGRG1 delivered via lentivirus for physiologic membrane presentation. ECD fragments produced in HEK293 to preserve native glycosylation. C-terminal tag enables BRET/flow-based cleavage monitoring. |
| Cross-species cyno/mouse evaluation (toxicity/safety) | Human / Cyno / Mouse ortholog ORF clones and proteins available with >95% purity; sequence identity confirmed. |
| Adhesion GPCR subfamily off-target liability | Homolog panel (ADGRG5, ADGRE5, ADGRG6) proteins strictly sequence-verified by mass spectrometry for counter-screening. |
| Lack of specific binding controls | ADGRG1 siRNA and benchmark reference antibody included for orthogonal specificity validation. |
Live ADGRG1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADGRG1 (GPR56) therapeutics is intensifying, with major players shifting focus from traditional mAbs to ADCs, CAR-T cellular therapies, and adhesion GPCR-specific modalities including Stachel-targeted agonists and allosteric modulators. As an adhesion GPCR broadly overexpressed in Acute Myeloid Leukemia (AML), glioblastoma, melanoma, and various solid tumors, ADGRG1 presents a highly specific tumor-associated antigen profile. The target remains in the emerging preclinical-to-early-discovery phase. First-generation therapies targeting the Collagen III binding interface or N-terminal fragment (NTF) are advancing toward lead optimization. The next wave of R&D is targeting constitutive activity modulation via the tethered agonist (Stachel) sequence exposed after autoproteolysis, along with combination regimens involving immune checkpoint inhibitors and tumor microenvironment regulators.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC / CAR-T | Early-stage Biotechs, Academic Spin-offs, Immuno-oncology Developers | AML, Glioblastoma, Colorectal Cancer, Solid Tumors | Internalization / Cytotoxicity (Need robust stable cell lines via Lentivirus); Cell surface expression validation (Need flow-validated target cells) |
| Monoclonal Antibody (Antagonist / Modulatory) | Emerging Biotech, Academic Labs, Specialized GPCR Platform Companies | Melanoma, Uveal Melanoma, Glioblastoma | Collagen III Displacement Assay (Need high-purity NTD-ECD); Cell-surface binding by Flow Cytometry (requires lentivirus-expressed full-length ADGRG1) |
| Stachel-Derived Peptide Agonist | Specialized GPCR Biotech | Fibrotic Diseases, Solid Tumors | Calcium Flux Assay (Need full-length stable cell line with native GPS cleavage) |
| Small Molecule Allosteric | Drug Discovery Platforms, Academic Consortia | CNS Disorders, Melanoma | Binding Site Verification (Need intact 7-TM domain and cross-species panel) |
| Genetic / siRNA Approach | Translational Oncology Institutes | Refractory Cancers | Knockdown validation (validated siRNA set provided) |
Key Differentiation Factors & Assay Strategy
For best-in-class ADGRG1 drug development, the following dimensions must be addressed:
- Affinity & Epitope Selection: Targeting the NTF (prone to shedding) vs. the CTF or GPS junction determines sink effect and tumor targeting efficiency. Use TarMart's lentivirus-expressed full-length cells for flow-based epitope mapping.
- Internalization Efficiency: For ADC/CAR-T, receptor internalization dictates potency. pH-sensitive dye labeling with live-cell imaging on ADGRG1 stable lines quantifies internalization.
- Ligand Blocking: Blocking interactions with endogenous ligands (TGM2, COL3A1) is a key mechanism. Use TarMart's ECD-Fc proteins for SPR/BLI competition assays.
- Cross-species & Off-target Selectivity: Antibodies must recognize human/cyno ADGRG1 and exclude ADGRG5, ADGRE5, ADGRG6. TarMart provides ortholog ORF clones and homolog protein panels.
- Safety: Avoid CNS toxicity by selecting antibodies specific for tumor-associated glycosylation variants. TarMart offers custom mutant proteins (e.g., GPS cleavage mutants) for counter-screening.